Current Standards for Treating Metastatic Urothelial Cancer
Risa Wong, MD, reviews the standard treatment options for patients with metastatic urothelial cancer.
Risa Wong, MD, hematology/oncology fellow at the University of Washington, reviews the standard treatment options for patients with metastatic urothelial cancer (mUC).
Patients with mUC who are defined as fit, are treated with first-line platinum-based combination chemotherapy as standard of care, explain Wong. In the past, after patients subsequently progressed, there were very limited options for subsequent therapy, and providers ended up retreating many of these patients with chemotherapy, either rechallenging them with a platinum-based regimen or switching to a nonplatinum-based chemotherapy regimen.
In recent years, there have been many advances in the treatment landscape and these patients can now receive immune checkpoint inhibitors.
Investigational FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer
October 28th 2024TYRA-300 showed promising safety and preliminary antitumor activity in FGFR3-altered metastatic urothelial cancer, with a 54.5% partial response rate and 100% disease control in the SURF301 trial.
Read More
